NCT03155620 2026-04-14Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting1,377 enrolled 10 charts
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03526250 2026-04-03Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Completed23 enrolled 11 charts